SAN DIEGO--(BUSINESS WIRE)--Third paragraph, sixth sentence of release should read: CNSide detected CSF tumor cells in all eleven measurements taken, compared to six of eleven using cytology. (instead of CNSide detected CSF tumor cells in all nine measurements taken, compared to five of nine using cytology.)
“Case Series of Multi-Institutional Utility of CNSide to Manage Leptomeningeal Disease in Patients with Metastatic Breast Cancer”
Tweet this
The updated release reads:
BIOCEPT’S CNSIDE CEREBROSPINAL FLUID ASSAY AIDS IN MONITORING TREATMENT RESPONSE AND DETECTS ACTIONABLE BIOMARKERS IN PATIENTS WITH METASTATIC BREAST CANCER
Case series poster to be presented at the Society for Neuro-Oncology Annual Meeting
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced the presentation of a multi-institutional case series showing that its CNSide cerebrospinal fluid assay helps physicians monitor treatment response and detects actionable mutations in patients with metastatic breast cancer and leptomeningeal disease (LMD). The poster will be presented virtually at the Society for Neuro-Oncology Annual Meeting in Boston, Nov. 19, 2021, from 7:30-9:30 p.m. ET, and Biocept will be exhibiting at booth #303.
Breast cancer is one of the most common cancers associated with LMD, a devastating complication in which cancer spreads to the membrane surrounding the brain and spinal cord. The current standard of care for...
Every couple of years, the same false stories come back. A claim that an election was rigged before a single vote was cast. An old video of violence, stripped of its date and place, presented as b...